Single infusion may prevent chronic headaches after concussion

NCT ID NCT07191145

Not yet recruiting Disease control Sponsor: Sunnybrook Health Sciences Centre Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This study tests whether a single infusion of eptinezumab, given within 8 weeks of a mild brain injury, can reduce headache days and prevent short-term post-traumatic headaches from becoming long-term. About 80 adults with migraine-like post-traumatic headaches will receive either the drug or a placebo. The main goal is to see if the drug lowers the number of moderate-to-severe headache days 3 months after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: eptinezumab
What this could lead to: If it works, this could provide a quick, single-infusion treatment to prevent short-term post-traumatic headaches from becoming chronic and disabling.
What could go wrong: This is a small, early-phase trial with only 80 people. The drug may not work better than placebo, and side effects like fatigue or nausea could occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POST TRAUMATIC HEADACHE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

migraine disorder Post-Traumatic Headache

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POST TRAUMATIC HEADACHE

Contacts and locations

Locations

Sunnybrook Health Sciences Centre

Toronto, Ontario, M4N 3M5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.